European CHMP recommends paediatric license extension of migalastat (Galafold)

The license extension is for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.

Source:

European Medicines Agency